RA Capital Nexus Fund III, L.P., Director at Mineralys Therapeutics, Inc. (MLYS), bought 1,296,296 shares at $13.50 ($17.5M) on 2025-03-13, disclosed to the SEC on 2025-03-17.
Open-market purchase of $17.5M MLYS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| MLYS | BUY | 2023-02-16 | $20.0M | — | Filing → |